

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

(B) Seq) GAO 1544 WE
PATENT
Attorney Docket No.: 018623-013410US
Client Reference No.: EPI 0134.10 US

On

7 Jan. 1999 2000

TOWNSEND and TOWNSEND and CREW LLP

By:

Malinda Adajit

RECEIVED

JAN 14 2000

TECH CENTER 1800/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Application No.: 09/189,702

Filed: November 10, 1998

For: HLA BINDING PEPTIDES AND
THEIR USES

Examiner: Schwadron, Ronald B.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Examiner's Communication mailed December 7, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 27, "Table 3", line 14, at the far right, insert the column heading

--SEQ ID NO:-- after "A*0201".